Standigm Inc., a Seoul, South Korea-based workflow artificial intelligence (AI) drug discovery company, raised $10m in funding.
Pavilion Capital made the investment.
The company intends to use the funds for the clinical research of AI-driven drug compounds and to strengthen its competitiveness in the global market.
Led by Jinhan Kim, co-founder and CEO, Standigm is a workflow AI-driven drug discovery company. The company has proprietary AI platforms encompassing novel target identification to lead generation to generate commercially valuable drug pipelines.
Founded in 2015, the company has established an early-stage drug discovery workflow AI to generate First-in-Class lead compounds within seven months. Pursuing full-stack, AI-driven industrializing drug discovery, Standigm has achieved the automation of molecular design workflow through DarkMolFactory™, and the automation effort has been expanding to the whole drug discovery process on the basis of Standigm AI platforms, including Standigm ASK™ for target discovery, Standigm BEST™ for lead design, and Standigm Insight™ for drug repurposing. To date, Standigm is running 22 in-house or collaborative drug pipelines using the workflow AI technology.
FinSMEs
06/07/2021